ライフサイエンスコーパス: chronic hepatitis B

1 diseases, which may open a new venue to cure chronic hepatitis B.

2 cination strategy for the functional cure of chronic hepatitis B.

3 foreign-born African Americans (FBAAs) with chronic hepatitis B.

4 on of antiviral therapeutics for the cure of chronic hepatitis B.

5 f serum samples from patients with acute and chronic hepatitis B.

6 of off-NA VR in patients with HBeAg-negative chronic hepatitis B.

7 patients with hepatitis B e antigen-negative chronic hepatitis B.

8 st controversial topics in the management of chronic hepatitis B.

9 shed nucleotide analogue in the treatment of chronic hepatitis B.

10 offer a potential new treatment strategy for chronic hepatitis B.

11 on, but limited data exist for patients with chronic hepatitis B.

12 in clinical development for the treatment of chronic hepatitis B.

13 l vectors, may be useful in the treatment of chronic hepatitis B.

14 after liver biopsy in a 10-year-old boy with chronic hepatitis B.

15 nagement of patients with HBeAg-seronegative chronic hepatitis B.

16 n therapies in immune-tolerant patients with chronic hepatitis B.

17 h potential for the therapeutic treatment of chronic hepatitis B.

18 tudy of immunotherapeutic approaches against chronic hepatitis B.

19 antiviral therapeutics for the treatment of chronic hepatitis B.

20 e to PEG-IFN in patients with HBeAg-positive chronic hepatitis B.

21 ermines the success of long-term therapy for chronic hepatitis B.

22 tion of treatment duration and cessation for chronic hepatitis B.

23 inical trials aiming at a functional cure of chronic hepatitis B.

24 to accelerating the discovery of a cure for chronic hepatitis B.

25 H0731 doses up to 300 mg in individuals with chronic hepatitis B.

26 during the natural history and treatment of chronic hepatitis B.

27 during the natural history and treatment of chronic hepatitis B.

28 cirrhosis is important for the management of chronic hepatitis B.

29 and foreseeable therapeutic developments in chronic hepatitis B.

30 ay be a good alternative to TDF for treating chronic hepatitis B.

31 sign of curative antiviral therapies against chronic hepatitis B.

32 ay mortality than noncirrhotic patients with chronic hepatitis B [4.4% vs 1.3%, adjusted odds ratio (

33 Chronic hepatitis B affects over 300 million people who

34 The prognosis in severe acute flares of chronic hepatitis B (AFOCHB) is often unclear.

35 ent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation.

36 analogue treatment exists for patients with chronic hepatitis B, although treatment is generally ant

37 s to achieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortali

38 specific immune cells in the pathogenesis of chronic hepatitis B and C and discusses recent findings

39 lly to treat other viral infections, such as chronic hepatitis B and C in humans.

40 Approximately 40% of chronic hepatitis B and C patients are susceptible to or

41 We identified chronic hepatitis B and C patients with healthcare utili

42 Chronic hepatitis B and C viral infections are major ris

43 Chronic hepatitis B and C virus infections are major cau

44 r reimbursed treatment) received therapy for chronic hepatitis B and C, respectively, by 2011.

45 ptibility and pathogenesis in the setting of chronic hepatitis B and C.

46 in serum samples from patients with acute vs chronic hepatitis B and controls.

47 Chronic hepatitis B and D infections are major causes of

48 ing uninfected pregnant women, patients with chronic hepatitis B and D virus (HBV/HDV) infection, and

49 r carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal.

50 global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections.

51 o reveal the molecular basis associated with chronic hepatitis B and IFN-alpha (IFNalpha) treatment r

52 undetectability are important milestones of chronic hepatitis B and major treatment endpoints of ant

53 gene that associated most significantly with chronic hepatitis B and outcomes to HBV infection in Asi

54 atitis B virus (HBV), the causative agent of chronic hepatitis B and prototypic hepadnavirus, is a sm

55 atobiliary cystadenocarcinoma in female with chronic hepatitis B and repeated hepatolithiasis.

56 There is no definite cure for chronic hepatitis B, and alpha interferon (IFN-alpha) is

57 elated to treatment outcome in patients with chronic hepatitis B are currently unknown.

58 ee of fibrosis, end-stage liver disease, and chronic hepatitis B at baseline (n = 485) were included.

59 ents with acute hepatitis B and C as well as chronic hepatitis B, C, and delta (D) patients were stud

60 Chronic hepatitis B carries a higher risk of death from

61 HBV genotype distribution between acute and chronic hepatitis B cases and the rapid decline in hepat

62 It is not known whether chronic hepatitis B (CH-B) or chronic hepatitis C (CH-C)

63 sponse to antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNA

64 129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B (CHB) and 488 with non-alcoholic fat

65 sis is a common histopathological feature of chronic hepatitis B (CHB) and has been associated with s

66 huck is used as an animal model for studying chronic hepatitis B (CHB) and HBV-associated hepatocellu

67 Chronic hepatitis B (CHB) and nonalcoholic fatty liver d

68 elopments in the evaluation and treatment of chronic hepatitis B (CHB) based on articles published be

69 the recent developments in the management of chronic hepatitis B (CHB) based on the articles publishe

70 elated liver cirrhosis and 115 patients with chronic hepatitis B (CHB) before and after 48 weeks of a

71 of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a

72 Inactive chronic hepatitis B (CHB) carriers make up the largest g

73 Chronic hepatitis B (CHB) comorbidity data are limited.

74 Chronic hepatitis B (CHB) exhibits a variety of clinical

75 Chronic hepatitis B (CHB) has become a treatable and con

76 M) treatment has been commonly used to treat Chronic Hepatitis B (CHB) in Asian countries based on TC

77 regulated gene transcripts in patients with chronic hepatitis B (CHB) in the absence of liver cirrho

78 Estimates of the prevalence of chronic hepatitis B (CHB) in the United States differ si

79 Chronic hepatitis B (CHB) infection acquired perinatally

80 The natural course of chronic hepatitis B (CHB) infection and treatment respon

81 s B surface antigen (HBsAg) seroclearance in chronic hepatitis B (CHB) infection are unknown.

82 Chronic hepatitis B (CHB) infection functional cure is d

83 Chronic hepatitis B (CHB) infection is the major cause o

84 ildren, but overall population prevalence of chronic hepatitis B (CHB) infection remains high.

85 Despite the high global prevalence of chronic hepatitis B (CHB) infection, datasets covering t

86 has been difficult to study in patients with chronic hepatitis B (CHB) infection.

87 r cirrhosis and/or hepatocellular carcinoma, chronic hepatitis B (CHB) is a major health problem.

88 Chronic hepatitis B (CHB) is a significant global health

89 Chronic hepatitis B (CHB) is associated with a dysfuncti

90 Chronic hepatitis B (CHB) is characterized by hepatic in

91 Antiviral therapy for chronic hepatitis B (CHB) is effective and can substanti

92 Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-

93 elationship between vitamin D metabolism and chronic hepatitis B (CHB) is less well characterized.

94 ong-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined.

95 -cure hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is unknown.

96 y of interferon alpha (IFNalpha) therapy for chronic hepatitis B (CHB) patients is about 40% and ofte

97 that the responses to IFN-alpha treatment of chronic hepatitis B (CHB) patients is influenced by IFN-

98 from healthy donors exposed to IFN-alpha and chronic hepatitis B (CHB) patients starting IFN-alpha th

99 to test this stopping rule in HBeAg-negative chronic hepatitis B (CHB) patients treated with entecavi

100 ls and methods to substitute liver biopsy in chronic hepatitis B (CHB) patients were investigated but

101 rial, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with compensated live

102 Th9 and Th17 cells were quantified in chronic hepatitis B (CHB) patients with hepatic fibrosis

103 patitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients.

104 of developing liver cancer and cirrhosis in chronic hepatitis B (CHB) patients.

105 B surface antigen (HBsAg) turnover rates in chronic hepatitis B (CHB) patients.

106 V DNA levels for inactive carrier status and chronic hepatitis B (CHB) progression in a community-bas

107 Children with immune-tolerant features of chronic hepatitis B (CHB) received entecavir once-daily

108 and their time relationship in patients with chronic hepatitis B (CHB) remain unclear.

109 nt of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) results in HBeAg loss in 30% o

110 f an electronic health record (EHR) alert on chronic hepatitis B (CHB) screening among at-risk Asian

111 Patients with chronic hepatitis B (CHB) usually acquire the virus peri

112 Globally, one third of prevalent chronic hepatitis B (CHB) virus infection (HBV) occurred

113 The clinical role of STAT3 in chronic hepatitis B (CHB) was also investigated.

114 ated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral lo

115 Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (

116 tive therapeutic target for the treatment of chronic hepatitis B (CHB), but it is challenging to stud

117 sponse to peginterferon (PEG-IFN) therapy in chronic hepatitis B (CHB), but previously proposed predi

118 In chronic hepatitis B (CHB), failure to control hepatitis

119 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-assoc

120 ti-HBsAg antibodies (HBsAb) in patients with chronic hepatitis B (CHB), often in the absence of amino

121 ctive factors against disease progression in chronic hepatitis B (CHB).

122 ndependent risk factor of liver cirrhosis in chronic hepatitis B (CHB).

123 tory responses can define clinical stages of chronic hepatitis B (CHB).

124 pecific T cells are functionally impaired in chronic hepatitis B (CHB).

125 st well-controlled viruses, in patients with chronic hepatitis B (CHB).

126 s B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB).

127 efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB).

128 viral activity in treatment of patients with chronic hepatitis B (CHB).

129 figure may underestimate true mortality from chronic hepatitis B (CHB).

130 t)ide analog (NA) treatment in patients with chronic hepatitis B (CHB).

131 role in control of viral replication during chronic hepatitis B (cHBV) infection, but little is know

132 Chronic hepatitis B develops more frequently in countrie

133 be used to guide management of patients with chronic hepatitis B due to high rates of misclassificati

134 TDF-treated patients with chronic hepatitis B have reduced bone mineral density, b

135 Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were t

136 d that lack of knowledge and awareness about chronic hepatitis B (HBV) and C virus (HCV) infections a

137 in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.

138 cellular enzymes may facilitate the cure of chronic hepatitis B.IMPORTANCE Persistent HBV infection

139 regimen that can induce a functional cure of chronic hepatitis B in a small, but significant, fractio

140 e the effectiveness of current therapies for chronic hepatitis B in clinical practice, given the ther

141 s to improve ascertainment and management of chronic hepatitis B in the region.

142 vels in serum were elevated in patients with chronic hepatitis B infection (CHB) and acute-on-chronic

143 Chronic hepatitis B infection (HBV) is major cause of mo

144 Chronic hepatitis B infection affects >300 million peopl

145 Eighty-one patients (39.3%) had chronic hepatitis B infection and 23 patients (11.2%) ha

146 among a national cohort of US veterans with chronic hepatitis B infection and examine risk factors f

147 th cirrhosis, 864 noncirrhotic controls with chronic hepatitis B infection, and 5468 noncirrhotic con

148 ation useful for management of patients with chronic hepatitis B infection.

149 iviral agent entecavir was commenced for his chronic hepatitis B infection.

150 of high genetic barrier for the treatment of chronic hepatitis B infection.

151 suggest immunotherapeutic strategies against chronic hepatitis B infection.

152 ope for treating adolescents and adults with chronic hepatitis B infection.

153 Current approaches to treatment for chronic hepatitis B involve suppression of hepatitis B v

154 Chronic hepatitis B is a serious liver disease and puts

155 Chronic hepatitis B is caused by prolonged infection wit

156 One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppr

157 ablish a persistent infection in people with chronic hepatitis B, leading to accelerated progression

158 ned the long-term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated

159 cination.IMPORTANCE A curative treatment for chronic hepatitis B must eliminate the virus from the li

160 he introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisa

161 People with chronic hepatitis B or C infection, or both, and those w

162 l chronic inflammatory liver diseases, e.g., chronic hepatitis B or C viral infection and steatohepat

163 dle-aged and elderly participants who had no chronic hepatitis B or C virus infection and received he

164 ar carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.

165 symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any conditi

166 symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any conditi

167 responses to these viruses in patients with chronic hepatitis B or C, and tailoring the dose of CD13

168 superinfection and sequelae in patients with chronic hepatitis B or C.

169 rom patients with acute hepatitis B, but not chronic hepatitis B or controls, hepatocytes expressed A

170 ified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 201

171 nd gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

172 ff-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear.

173 atitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-2

174 nd CD4+ T cells from healthy donors and from chronic hepatitis B patients became polyfunctional effec

175 umerically and functionally impaired pDCs of chronic hepatitis B patients demonstrated reduced PI3K-P

176 Among 2338 chronic hepatitis B patients followed during 2006-2013 i

177 hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy wit

178 Chronic hepatitis B patients with high viral loads are a

179 lone without hepatitis B immune globulin for chronic hepatitis B patients with preexisting lamivudine

180 Fifty-seven consecutive chronic hepatitis B patients with preexisting rt204 LAM-

181 cohort study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who

182 Among 1635 chronic hepatitis B patients, 978 (59.8%) were immune or

183 eyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with

184 i-fibrotic activity compared with those from chronic hepatitis B patients, which were mainly mediated

185 They may be used for clinical management of chronic hepatitis B patients.

186 ersons vaccinated in infancy, an analysis of chronic hepatitis B prevalence in racial and ethnic popu

187 therapy might be developed for patients with chronic hepatitis B, regardless of their HLA type.

188 he majority of persons currently treated for chronic hepatitis B require long-term or lifelong therap

189 with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B respond to treatment with peginterfe

190 -) ) patients and 266 HBeAg(+) patients with chronic hepatitis B (some nucleoside-naive and some lami

191 In patients with chronic hepatitis B, TAF appears to be as effective as T

192 unotherapeutic strategy for the treatment of chronic hepatitis B, the efficiencies were not adequate

193 ha (IFN-alpha) is an approved medication for chronic hepatitis B therapy.

194 Most individuals with chronic hepatitis B viral (HBV) infection acquired the i

195 Chronic hepatitis B viral (HBV) infection remains a sign

196 is a clinical indicator of poor outcome for chronic hepatitis B viral (HBV) infection.

197 jor mechanisms underlying the development of chronic hepatitis B viral infection.

198 The largest increases were from chronic hepatitis B virus (HBV) (+71), liver transplanta

199 Chronic hepatitis B virus (HBV) and hepatitis C virus (H

200 Chronic hepatitis B virus (HBV) and hepatitis C virus (H

201 Chronic hepatitis B virus (HBV) and hepatitis C virus (H

202 gnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (H

203 In patients with chronic hepatitis B virus (HBV) and hepatitis C virus (H

204 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (H

205 epatitis C virus (HCV) and 203 patients with chronic hepatitis B virus (HBV) before antiviral treatme

206 graphic characteristics and comorbidities to chronic hepatitis B virus (HBV) controls using propensit

207 Chronic hepatitis B virus (HBV) infection affects 240 mi

208 Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire pr

209 w the strongest genome-wide association with chronic hepatitis B virus (HBV) infection and HBV recove

210 s, on proliferation of LPCs in patients with chronic hepatitis B virus (HBV) infection and in mice.

211 cohort of 203 treatment-naive patients with chronic hepatitis B virus (HBV) infection and tested for

212 Therapies for chronic hepatitis B virus (HBV) infection are urgently n

213 d in antiviral treatment-naive patients with chronic hepatitis B virus (HBV) infection but not in tre

214 ference (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a

215 causes resistance to IFN therapy.IMPORTANCE Chronic hepatitis B virus (HBV) infection continues to b

216 Chronic hepatitis B virus (HBV) infection has been assoc

217 Through migration, diversity of chronic hepatitis B virus (HBV) infection has changed, a

218 Patients with chronic hepatitis B virus (HBV) infection have a high ri

219 he two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-infer

220 he two drugs in patients with HBeAg-positive chronic hepatitis B virus (HBV) infection in a non-infer

221 rs associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North Ameri

222 The number of persons with chronic hepatitis B virus (HBV) infection in the United

223 Chronic hepatitis B virus (HBV) infection is a common ca

224 Chronic hepatitis B virus (HBV) infection is a global pu

225 Chronic hepatitis B virus (HBV) infection is a global pu

226 Chronic hepatitis B virus (HBV) infection is a global pu

227 Chronic hepatitis B virus (HBV) infection is a major fac

228 Chronic hepatitis B virus (HBV) infection is a major glo

229 Chronic hepatitis B virus (HBV) infection is a major pub

230 Chronic hepatitis B virus (HBV) infection is a major ris

231 Chronic hepatitis B virus (HBV) infection is a major ris

232 Chronic hepatitis B virus (HBV) infection is a major ris

233 Chronic hepatitis B virus (HBV) infection is a major ris

234 Chronic hepatitis B virus (HBV) infection is a risk fact

235 Chronic hepatitis B virus (HBV) infection is estimated t

236 Chronic Hepatitis B Virus (HBV) infection is generally n

237 Chronic hepatitis B virus (HBV) infection is partly resp

238 Chronic hepatitis B virus (HBV) infection is prevalent,

239 A hallmark of chronic hepatitis B virus (HBV) infection is the functio

240 s B e antigen (HBeAg)-negative patients with chronic hepatitis B virus (HBV) infection is unknown.

241 Chronic hepatitis B virus (HBV) infection often develop

242 The heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the co

243 Chronic hepatitis B virus (HBV) infection remains the mo

244 t strategy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknow

245 (known as functional cure) in patients with chronic hepatitis B virus (HBV) infection significantly

246 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops

247 ican nations have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but

248 Of 2202 patients with chronic hepatitis B virus (HBV) infection, 50% were aged

249 There are 257 million persons worldwide with chronic hepatitis B virus (HBV) infection, a leading cau

250 Chronic hepatitis B virus (HBV) infection, a serious pub

251 Although there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies ar

252 In patients with chronic hepatitis B virus (HBV) infection, persistent ex

253 For mothers with chronic hepatitis B virus (HBV) infection, the Centers f

254 Using a transgenic mouse model of chronic hepatitis B virus (HBV) infection, we evaluated

255 ms that govern distinct clinical phases of a chronic hepatitis B virus (HBV) infection-immune toleran

256 and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

257 nfections and are particularly promising for chronic hepatitis B virus (HBV) infection.

258 ear from the liver diseases that result from chronic hepatitis B virus (HBV) infection.

259 unomodulatory effect are rarely addressed in chronic hepatitis B virus (HBV) infection.

260 titis B surface Ag (HBsAg) seroconversion in chronic hepatitis B virus (HBV) infection.

261 ot been extensively studied in patients with chronic hepatitis B virus (HBV) infection.

262 ronic hepatic complications in patients with chronic hepatitis B virus (HBV) infection.

263 but no studies have focused on patients with chronic hepatitis B virus (HBV) infection.

264 us (WHV) represent the best animal model for chronic hepatitis B virus (HBV) infection.

265 component of a treatment regimen for curing chronic hepatitis B virus (HBV) infection.

266 ded during the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection.

267 lular carcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

268 Chronic hepatitis B virus (HBV) infections are associate

269 rn of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China rema

270 Chronic hepatitis B virus (HBV) infections result in 887

271 rsion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections.

272 CC) are associated with cirrhosis related to chronic hepatitis B virus (HBV) or hepatitis C virus (HC

273 and 2013, we identified 35,356 patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HC

274 ons, strongyloidiasis from most regions, and chronic hepatitis B virus (HBV) particularly in Asian im

275 ) in low-replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

276 s and hepatocellular carcinoma (HCC) risk in chronic hepatitis B virus (HBV) patients.

277 the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to g

278 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV)

279 ediated disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer

280 onse is compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also

281 Chronic hepatitis B virus carriers are at risk of develo

282 European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucle

283 Currently 247 million people are living with chronic hepatitis B virus infection (CHB), and the devel

284 IL-10 is elevated in patients with chronic hepatitis B virus infection (CHB), but its cellu

285 Chronic hepatitis B virus infection is a leading cause o

286 s a therapeutic strategy in the treatment of chronic hepatitis B virus infection or other chronic vir

287 Chronic hepatitis B virus infection predicted longer sur

288 h liver fibrosis, as were daily alcohol use, chronic hepatitis B virus infection, body mass index gre

289 nisms of immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strat

290 us-specific T-cell immunity in patients with chronic hepatitis B virus infection.

291 Fewer than 1% of chronic hepatitis B virus infections per year are cured

292 Chronic hepatitis B virus or hepatitis C co-infection wa

293 ression on viral-responding CD8 T cells from chronic hepatitis B virus patients.

294 ne samples from HBeAg-positive patients with chronic hepatitis B were analyzed.

295 hypertension, type 2 diabetes mellitus, and chronic hepatitis B with cirrhosis presented with a 2-we

296 Differences between patients with chronic hepatitis B with HBsAg clearance and nonresponde

297 reactivation after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance

298 ferent disease phases of young patients with chronic hepatitis B, with emphasis on the so-called immu

299 ising therapeutic option in the treatment of chronic hepatitis B, with our lead candidate now enterin

300 Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrh